Tentt

Piramal Pharma Completes Kenalog Product Acquisition

Closed
HealthcareDivestiture

Deal Overview

Piramal Pharma has completed the acquisition of the Kenalog injectable product from Bristol-Myers Squibb. The transaction is described as a divestiture and is marked closed.

The excerpt provides no additional deal economics, product scope details, or closing timing beyond completion.

Key Details

Transaction
Piramal Pharma acquires Kenalog Injectable Product

Filed under

Source

Read full article on scanx.trade

via GN - completed acquisition of · April 1, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →